Australia's most trusted
source of pharma news
Tuesday, 02 December 2025
Posted 2 December 2025 AM
The last round of PBS listings for the year have dropped with seven drugs nabbing the final reimbursements of 2025, including a next-gen PD-1 inhibitor.
Dr Reddy's immunotherapy Zytorvi was recommended by PBAC in July and is the first and only targeted treatment for nasopharyngeal cancer (NPC), a rare and aggressive form of head and neck cancer. About 200 Australians are diagnosed with NPC each year, most predominantly men over the age of 40.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.